The estimated Net Worth of Geoffrey M. Parker is at least $5.79 Million dollars as of 14 May 2024. Mr. Parker owns over 8,764 units of Tricida Inc stock worth over $2,692 and over the last 13 years he sold TCDA stock worth over $3,008,908. In addition, he makes $2,782,190 as Chief Financial Officer and Executive Vice President at Tricida Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Parker TCDA stock SEC Form 4 insiders trading
Geoffrey has made over 49 trades of the Tricida Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 8,764 units of TCDA stock worth $264,848 on 14 May 2024.
The largest trade he's ever made was buying 60,000 units of Tricida Inc stock on 2 July 2018 worth over $1,140,000. On average, Geoffrey trades about 9,658 units every 54 days since 2012. As of 14 May 2024 he still owns at least 24,469 units of Tricida Inc stock.
You can see the complete history of Mr. Parker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Geoffrey Parker biography
Geoffrey M. Parker serves as Chief Financial Officer, Executive Vice President of the Company. Mr. Parker has served as our Senior Vice President and Chief Financial Officer since April 2017. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, Inc. from September 2010 to May 2015. From 1997 to 2009, Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs. Mr. Parker has served as a member of the board of directors of Perrigo Company plc, Genomic Health, Inc., and ChemoCentryx, Inc. since November 2016, June 2016, and December 2009, respectively. Mr. Parker was also a member of the board of directors of Sunesis Pharmaceuticals, Inc. from March 2016 until December 2017. Mr. Parker holds an AB degree in Economics and Engineering Sciences from Dartmouth College and an M.B.A. from Stanford University.
What is the salary of Geoffrey Parker?
As the Chief Financial Officer and Executive Vice President of Tricida Inc, the total compensation of Geoffrey Parker at Tricida Inc is $2,782,190. There are 2 executives at Tricida Inc getting paid more, with Gerrit Klaerner having the highest compensation of $10,168,700.
How old is Geoffrey Parker?
Geoffrey Parker is 55, he's been the Chief Financial Officer and Executive Vice President of Tricida Inc since 2019. There are 10 older and 6 younger executives at Tricida Inc. The oldest executive at Tricida Inc is Robert Alpern, 69, who is the Independent Director.
What's Geoffrey Parker's mailing address?
Geoffrey's mailing address filed with the SEC is 210 EAST GRAND AVE, , SOUTH SAN FRANCISCO, , 94080.
Insiders trading at Tricida Inc
Over the last 6 years, insiders at Tricida Inc have traded over $198,373,537 worth of Tricida Inc stock and bought 7,174,449 units worth $105,536,837 . The most active insiders traders include David P Bonita, Advisors Llc Orbi Med Capit..., and Healthcare Capital Partners.... On average, Tricida Inc executives and independent directors trade stock every 8 days with the average trade being worth of $22,553. The most recent stock trade was executed by Robert J Alpern on 23 November 2022, trading 131,879 units of TCDA stock currently worth $27,695.
What does Tricida Inc's logo look like?
Complete history of Mr. Parker stock trades at ChemoCentryx Inc, Sunesis Pharmaceuticals Inc, Perrigo plc, Tricida Inc, and Allogene Therapeutics Inc
Tricida Inc executives and stock owners
Tricida Inc executives and other stock owners filed with the SEC include:
-
Gerrit Klaerner,
President, Chief Executive Officer, Director -
Dawn Parsell,
Executive Vice President - Clinical Development -
Geoffrey Parker,
Chief Financial Officer, Executive Vice President -
Edward Hejlek,
Senior Vice President -
Dr. Gerrit Klaerner Ph.D.,
Founder, Pres, CEO & Exec. Director -
Dr. Dawn Parsell Ph.D.,
Exec. VP of Clinical Devel. -
Geoffrey M. Parker,
COO, CFO & Exec. VP -
Robert L. McKague J.D.,
Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer -
Dr. Wilhelm Stahl,
Exec. VP & CTO -
Klaus Veitinger,
Independent Chairman of the Board -
David Bonita,
Independent Director -
Kathryn Falberg,
Independent Director -
David Hirsch,
Independent Director -
Sandra Coufal,
Independent Director -
Robert Alpern,
Independent Director -
Marc Cobo,
Senior Vice President - Finance, Chief Accounting Officer -
Robert McKague,
Executive Vice President, General Counsel, Secretary -
Edward J. Hejlek Esq., J.D.,
Exec. VP of Intellectual Property -
Jackie Cossmon,
VP of Investor Relations & Communications -
Annie Yoshiyama,
VP of Fin. & Chief Accounting Officer -
Claire Lockey,
Chief Dev. Officer and Sr. VP -
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Ven...,
-
Beek Jeroen B Van,
Chief Comm Officer and Sr VP -
Steffen Pietzke,
VP Fin & Chief Acct Officer -
Capital Partners Ii, Llc Lo...,
-
Advisors Llc Orbi Med Capit...,
-
Harbor Master Investors (Ca...,
10% owner -
Wilhelm Stahl,
EVP, Chief Tech Officer -
Brian M.Sibling Capital Ven...,
-
Susannah Cantrell,
EVP, Chief Comm. Officer -
Brian M.Sibling Capital Fun...,
-
Brian M.Sibling Capital Fun...,
-
Annie Yoshiyama,
Senior VP, Finance and CAO -
Healthcare Capital Partners...,